179 related articles for article (PubMed ID: 31925976)
1. High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer.
Bo X; Wang J; Wang C; Nan L; Gao Z; Xin Y; Li M; Shen S; Liu H; Ni X; Suo T; Zhang D; Lu P; Wang Y; Liu H
Cancer Sci; 2020 Mar; 111(3):817-825. PubMed ID: 31925976
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients.
Bo X; Wang J; Suo T; Ni X; Liu H; Shen S; Li M; Wang Y; Liu H; Xu J
BMC Cancer; 2018 Mar; 18(1):313. PubMed ID: 29562907
[TBL] [Abstract][Full Text] [Related]
3. Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients.
Espinoza JA; García P; Bizama C; Leal JL; Riquelme I; Weber H; Macanas P; Aguayo G; Viñuela E; Roa JC; Nervi B
Histopathology; 2016 Apr; 68(5):722-8. PubMed ID: 26266900
[TBL] [Abstract][Full Text] [Related]
4. GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer.
Ichimiya S; Onishi H; Nagao S; Koga S; Sakihama K; Nakayama K; Fujimura A; Oyama Y; Imaizumi A; Oda Y; Nakamura M
Oncol Rep; 2021 Mar; 45(3):997-1010. PubMed ID: 33650666
[TBL] [Abstract][Full Text] [Related]
5. High CD8
Fluxá P; Rojas-Sepúlveda D; Gleisner MA; Tittarelli A; Villegas P; Tapia L; Rivera MT; López MN; Catán F; Uribe M; Salazar-Onfray F
BMC Cancer; 2018 Mar; 18(1):243. PubMed ID: 29499656
[TBL] [Abstract][Full Text] [Related]
6. Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine.
Yang C; Xu M; Shen HJ; Zhu HY; Li F; He M; Chen T; Wang J; Shi WJ; Ji F
Int J Clin Exp Pathol; 2014; 7(2):521-8. PubMed ID: 24551272
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.
Ostwal V; Swami R; Patkar S; Majumdar S; Goel M; Mehta S; Engineer R; Mandavkar S; Kumar S; Ramaswamy A
Med Oncol; 2018 Mar; 35(4):57. PubMed ID: 29564657
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy.
Xu S; Jiang C; Lin R; Wang X; Hu X; Chen W; Chen X; Chen T
J Exp Clin Cancer Res; 2021 Nov; 40(1):373. PubMed ID: 34823564
[TBL] [Abstract][Full Text] [Related]
9. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
Duffy A; Capanu M; Abou-Alfa GK; Huitzil D; Jarnagin W; Fong Y; D'Angelica M; Dematteo RP; Blumgart LH; O'Reilly EM
J Surg Oncol; 2008 Dec; 98(7):485-9. PubMed ID: 18802958
[TBL] [Abstract][Full Text] [Related]
10. Calreticulin: a potential diagnostic and therapeutic biomarker in gallbladder cancer.
Ye J; Qi L; Du Z; Yu L; Chen K; Li R; Feng R; Zhai W
Aging (Albany NY); 2021 Feb; 13(4):5607-5620. PubMed ID: 33591948
[TBL] [Abstract][Full Text] [Related]
11. α-Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades.
Shi Y; Fan Y; Hu Y; Jing J; Wang C; Wu Y; Geng Q; Dong X; Li E; Dong D
J Cell Mol Med; 2020 Jan; 24(1):760-771. PubMed ID: 31762191
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin.
You MS; Ryu JK; Choi YH; Choi JH; Huh G; Paik WH; Lee SH; Kim YT
BMC Cancer; 2019 Jan; 19(1):10. PubMed ID: 30611225
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE.
Zhang GF; Wu JC; Wang HY; Jiang WD; Qiu L
Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32869841
[TBL] [Abstract][Full Text] [Related]
14. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
[TBL] [Abstract][Full Text] [Related]
15. Increased co-expression of PD1 and TIM3 is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer.
He X; Peng Y; He G; Ye H; Liu L; Zhou Q; Shi J; Fu S; Wang J; Zhou Z; Li W
J Transl Med; 2023 Oct; 21(1):717. PubMed ID: 37828574
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo.
Wang W; Hu Z; Huang Y; Zheng H; Sun Q; Yang Q; Zhang Y; Zhang L; Wang W
Biomed Res Int; 2019; 2019():9205851. PubMed ID: 31019975
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer.
Oguro S; Ino Y; Shimada K; Hatanaka Y; Matsuno Y; Esaki M; Nara S; Kishi Y; Kosuge T; Hiraoka N
Cancer Sci; 2015 Dec; 106(12):1750-60. PubMed ID: 26395180
[TBL] [Abstract][Full Text] [Related]
18. Mast cell density in metastatic renal cell carcinoma: Association with prognosis and tumour-infiltrating lymphocytes.
Yao J; Xi W; Chen X; Xiong Y; Zhu Y; Wang H; Hu X; Guo J
Scand J Immunol; 2021 Apr; 93(4):e13006. PubMed ID: 33275792
[TBL] [Abstract][Full Text] [Related]
19. aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
Tian L; Lu Y; Yang T; Deng Z; Xu L; Yao W; Ma C; Li X; Zhang J; Liu Y; Wang J
Redox Biol; 2019 Apr; 22():101149. PubMed ID: 30822690
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of immune cells in the tumor microenvironment and peripheral blood of gallbladder carcinoma patients.
Zhang Y; Ma C; Wang M; Hou H; Cui L; Jiang C; Sun J; Qu X
Clin Transl Oncol; 2017 Apr; 19(4):477-488. PubMed ID: 27718154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
